|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Moghimi-Dehkordi B and Safaee A: An
overview of colorectal cancer survival rates and prognosis in Asia.
World J Gastro Oncol. 4:71–75. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hayat MJ, Howlader N, Reichman ME and
Edwards BK: Cancer statistics, trends, and multiple primary cancer
analyses from the surveillance, epidemiology, and end results
(SEER) Program. Oncologist. 12:20–37. 2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang M, Liu T, Sun H, Weng W, Zhang Q,
Liu C, Han Y and Sheng W: Pim1 supports human colorectal cancer
growth during glucose deprivation by enhancing the Warburg effect.
Cancer Sci. 109:1468–1479. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Taniguchi K, Sakai M, Sugito N, Kumazaki
M, Shinohara H, Yamada N, Nakayama T, Ueda H, Nakagawa Y, Ito Y, et
al: PTBP1-associated microRNA-1 and -133b suppress the Warburg
effect in colorectal tumors. Oncotarget. 7:18940–18952.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nijhuis A, Thompson H, Adam J, Parker A,
Gammon L, Lewis A, Bundy JG, Soga T, Jalaly A, Propper D, et al:
Remodelling of microRNAs in colorectal cancer by hypoxia alters
metabolism profiles and 5-fluorouracil resistance. Hum Mol Genet.
26:1552–1564. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Vartanian A, Agnihotri S, Wilson MR,
Burrell KE, Tonge PD, Alamsahebpour A, Jalali S, Taccone MS,
Mansouri S, Golbourn B, et al: Targeting hexokinase 2 enhances
response to radio-chemotherapy in glioblastoma. Oncotarget.
7:69518–69535. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Jin Z, Gu J, Xin X, Li Y and Wang H:
Expression of hexokinase 2 in epithelial ovarian tumors and its
clinical significance in serous ovarian cancer. Eur J Gynaecol
Oncol. 35:519–524. 2014.PubMed/NCBI
|
|
13
|
Graziano F, Ruzzo A, Giacomini E,
Ricciardi T, Aprile G, Loupakis F, Lorenzini P, Ongaro E, Zoratto
F, Catalano V, et al: Glycolysis gene expression analysis and
selective metabolic advantage in the clinical progression of
colorectal cancer. Pharmacogenomics J. 17:258–264. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Katagiri M, Karasawa H, Takagi K, Nakayama
S, Yabuuchi S, Fujishima F, Naitoh T, Watanabe M, Suzuki T, Unno M
and Sasano H: Hexokinase 2 in colorectal cancer: A potent
prognostic factor associated with glycolysis, proliferation and
migration. Histol Histopathol. 32:351–360. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kudryavtseva AV, Fedorova MS, Zhavoronkov
A, Moskalev AA, Zasedatelev AS, Dmitriev AA, Sadritdinova AF,
Karpova IY, Nyushko KM, et al: Effect of lentivirus-mediated shRNA
inactivation of HK1, HK2, and HK3 genes in colorectal cancer and
melanoma cells. BMC Genet. 17 (Suppl 3)(S156)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Alvarez-Garcia I and Miska EA: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Treiber T, Treiber N and Meister G:
Regulation of microRNA biogenesis and function. Thromb Haemost.
107:605–610. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhao Y and Srivastava D: A developmental
view of microRNA function. Trends Biochem Sci. 32:189–197.
2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mo YY: MicroRNA regulatory networks and
human disease. Cell Mol Life Sci. 69:3529–3531. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Moridikia A, Mirzaei H, Sahebkar A and
Salimian J: MicroRNAs: Potential candidates for diagnosis and
treatment of colorectal cancer. J Cell Physiol. 233:901–913.
2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Slattery ML, Herrick JS, Pellatt DF,
Stevens JR, Mullany LE, Wolff E, Hoffman MD, Samowitz WS and Wolff
RK: MicroRNA profiles in colorectal carcinomas, adenomas and normal
colonic mucosa: Variations in miRNA expression and disease
progression. Carcinogenesis. 37:245–261. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
You C, Liang H, Sun W, Li J, Liu Y, Fan Q,
Zhang H, Yue X, Li J, Chen X and Ba Y: Deregulation of the
miR-16-KRAS axis promotes colorectal cancer. Sci Rep.
6(37459)2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Huang C, Liu J, Xu L, Hu W, Wang J, Wang M
and Yao X: MicroRNA-17 promotes cell proliferation and migration in
human colorectal cancer by downregulating SIK1. Cancer Manag Res.
11:3521–3534. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhang X, Li X, Tan F, Yu N and Pei H:
STAT1 inhibits MiR-181a expression to suppress colorectal cancer
cell proliferation through PTEN/Akt. J Cell Biochem. 118:3435–3443.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sun Y, Zhao X, Zhou Y and Hu Y: miR-124,
miR-137 and miR-340 regulate colorectal cancer growth via
inhibition of the Warburg effect. Oncol Rep. 28:1346–1352.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33(e179)2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Oparina NY, Snezhkina AV, Sadritdinova AF,
Veselovskii VA, Dmitriev AA, Senchenko VN, Mel'nikova NV,
Speranskaya AS, Darii MV, Stepanov OA, et al: Differential
expression of genes that encode glycolysis enzymes in kidney and
lung cancer in humans. Genetika. 49:814–823. 2013.PubMed/NCBI View Article : Google Scholar : (In Russian).
|
|
29
|
He Y, Deng F, Zhao S, Zhong S, Zhao J,
Wang D, Chen X, Zhang J, Hou J, Zhang W, et al: Analysis of
miRNA-mRNA network reveals miR-140-5p as a suppressor of breast
cancer glycolysis via targeting GLUT1. Epigenomics. 11:1021–1036.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Markopoulos GS, Roupakia E, Tokamani M,
Chavdoula E, Hatziapostolou M, Polytarchou C, Marcu KB,
Papavassiliou AG, Sandaltzopoulos R and Kolettas E: A step-by-step
microRNA guide to cancer development and metastasis. Cell Oncol
(Dordr). 40:303–339. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng
X and Yu B: miR-513a-3p sensitizes human lung adenocarcinoma cells
to chemotherapy by targeting GSTP1. Lung Cancer. 77:488–494.
2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
da Silveira MB, Lima KF, da Silva AR, Dos
Santos RAS and Moraes KCM: Mir-513a-3p contributes to the
controlling of cellular migration processes in the A549 lung tumor
cells by modulating integrin β-8 expression. Mol Cell Biochem.
444:43–52. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ju HQ, Zhan G, Huang A, Sun Y, Wen S, Yang
J, Lu WH, Xu RH, Li J, Li Y, et al: ITD mutation in FLT3 tyrosine
kinase promotes Warburg effect and renders therapeutic sensitivity
to glycolytic inhibition. Leukemia. 31:2143–2150. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lee HG, Kim H, Son T, Jeong Y, Kim SU,
Dong SM, Park YN, Lee JD, Lee JM and Park JH: Regulation of HK2
expression through alterations in CpG methylation of the HK2
promoter during progression of hepatocellular carcinoma.
Oncotarget. 7:41798–41810. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Patra KC, Wang Q, Bhaskar PT, Miller L,
Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, et al:
Hexokinase 2 is required for tumor initiation and maintenance and
its systemic deletion is therapeutic in mouse models of cancer.
Cancer Cell. 24:213–228. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Iwamoto M, Kawada K, Nakamoto Y, Itatani
Y, Inamoto S, Toda K, Kimura H, Sasazuki T, Shirasawa S, Okuyama H,
et al: Regulation of 18F-FDG accumulation in colorectal cancer
cells with mutated KRAS. J Nucl Med. 55:2038–2044. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhu W, Huang Y, Pan Q, Xiang P, Xie N and
Yu H: MicroRNA-98 suppress warburg effect by targeting HK2 in colon
cancer cells. Dig Dis Sci. 62:660–668. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Jin F, Wang Y, Zhu Y, Li S, Liu Y, Chen C,
Wang X, Zenz K and Li L: The miR-125a/HK2 axis regulates cancer
cell energy metabolism reprogramming in hepatocellular carcinoma.
Sci Rep. 7(3089)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Li Q, Qin Y, Wei P, Lian P, Li Y, Xu Y, Li
X, Li D and Cai S: Gas1 inhibits metastatic and metabolic
phenotypes in colorectal carcinoma. Mol Cancer Res. 14:830–840.
2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Hamabe A, Yamamoto H, Konno M, Uemura M,
Nishimura J, Hata T, Takemasa I, Mizushima T, Nishida N, Kawamoto
K, et al: Combined evaluation of hexokinase 2 and phosphorylated
pyruvate dehydrogenase-E1α in invasive front lesions of colorectal
tumors predicts cancer metabolism and patient prognosis. Cancer
Sci. 105:1100–1108. 2014.PubMed/NCBI View Article : Google Scholar
|
